Humanigen
Biopharmaceutical company that focuses on developing human antibody therapeutics.
Launch date
Employees
Market cap
CAD211k
Enterprise valuation
(CAD29m) (Public information from Jan 2024)
Share price
$0 HGEN
Brisbane California (HQ)
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | <1m | 3.6m | 2.5m | <1m |
| % growth | - | - | - | - | 1052 % | (30 %) | (92 %) |
| EBITDA | (19.0m) | (11.3m) | (8.9m) | (88.2m) | (234m) | (67.8m) | - |
| % EBITDA margin | - | - | - | (28269 %) | (6520 %) | (2697 %) | - |
| Profit | (22.0m) | (12.0m) | (10.3m) | (89.5m) | (237m) | (70.7m) | - |
| % profit margin | - | - | - | (28697 %) | (6583 %) | (2813 %) | - |
| EV / revenue | - | - | - | 2678.2x | 53.5x | 1.6x | - |
| EV / EBITDA | -1.3x | -7.0x | -6.9x | -9.5x | -0.8x | -0.1x | - |
| R&D budget | - | - | 2.6m | 72.7m | 213m | 55.2m | - |
| R&D % of revenue | - | - | - | 23305 % | 5928 % | 2196 % | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | - | ||
$4.0m | Seed | ||
$20.0m | Series B | ||
| N/A | $20.0m | Series C | |
$20.0m | Series D | ||
$12.0m | Series D | ||
| N/A | $17.0m | Growth Equity VC | |
| N/A | N/A | IPO | |
| N/A | $12.2m | Post IPO Equity | |
$11.0m | Post IPO Equity | ||
| N/A | $5.0m | Post IPO Debt | |
N/A | Grant | ||
$80.0m | Post IPO Debt | ||
| Total Funding | CAD127m | ||
Recent News about Humanigen
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.